Certain Common Stock of Biodesix, Inc. are subject to a Lock-Up Agreement Ending on 5-JUL-2024.
July 04, 2024
Share
Certain Common Stock of Biodesix, Inc. are subject to a Lock-Up Agreement Ending on 5-JUL-2024. These Common Stock will be under lockup for 91 days starting from 5-APR-2024 to 5-JUL-2024.
Details:
The Company s directors and officers and certain holders of our outstanding common stock have agreed that, without the prior written consent of TD Securities (USA) LLC and William Blair & Company, LLC, we and they will not, and will not publicly disclose an intention to, during the period ending 90 days after the date of this prospectus supplement.
Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.
BIODESIX, INC. 
